

Title (en)
METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS

Title (de)
VERFAHREN ZUR IDENTIFIZIERUNG THERAPEUTISCH EFFEKTIVER ANTINEOPLASTISCHER SUBSTANZEN MITTELS KULTIVierter ZELLEN MIT INTAKTEN ZELLMEMBRANEN UND DAMIT ZUSAMMENHÄNGENDE PRODUKTE

Title (fr)
TECHNIQUES D'IDENTIFICATION D'AGENTS ANTINEOPLASTIQUES THERAPEUTIQUEMENT EFFICACES AVEC DES CELLULES DE CULTURE A MEMBRANE CELLULAIRE INTACTE ET PRODUITS CORRESPONDANT

Publication
EP 1151295 A4 20050330 (EN)

Application
EP 00907081 A 20000201

Priority
• US 0002329 W 20000201
• US 11810299 P 19990201
• US 45459599 A 19991207

Abstract (en)
[origin: WO0045165A1] A method for identifying potentially therapeutically effective antineoplastic compounds comprising determining the ability of test compounds to act as activators of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane and expressing a cancer phenotype, wherein a test compound that enhances caspase cascade activity is determined to have potential therapeutic efficacy. The method specifically differentiates activators of the caspase cascade from non-specific cell poisons. A therapeutic method useful to modulate in vivo apoptosis or in vivo neoplastic disease, comprising administering to a subject an effective amount of a compound identified as a caspase cascade activator is provided. Compounds, pharmaceutical compositions and a kit for performing the therapeutic method are further provided.

IPC 1-7
G01N 33/50

IPC 8 full level
A61K 31/00 (2006.01); **A61K 31/352** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/4188** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/453** (2006.01); **A61K 31/475** (2006.01); **A61K 31/496** (2006.01); **A61K 31/5377** (2006.01); **A61K 31/5513** (2006.01); **A61K 31/675** (2006.01); **C07D 493/20** (2006.01); **C07D 493/22** (2006.01); **C07D 519/00** (2006.01); **C12Q 1/37** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP)
A61K 31/00 (2013.01); **A61K 31/352** (2013.01); **A61K 31/4025** (2013.01); **A61K 31/4178** (2013.01); **A61K 31/4188** (2013.01); **A61K 31/4433** (2013.01); **A61K 31/453** (2013.01); **A61K 31/475** (2013.01); **A61K 31/496** (2013.01); **A61K 31/5377** (2013.01); **A61K 31/5513** (2013.01); **A61K 31/675** (2013.01); **C07D 493/20** (2013.01); **C07D 493/22** (2013.01); **C07D 519/00** (2013.01); **C12Q 1/37** (2013.01); **G01N 33/5011** (2013.01); **G01N 2500/10** (2013.01)

Citation (search report)
• [XY] WO 9855863 A1 19981210 - IDUN PHARMACEUTICALS INC [US]
• [Y] US 5821072 A 19981013 - SCHWARTZ GARY K [US], et al
• [A] WO 9853091 A1 19981126 - BURNHAM INST [US]
• [X] FULDA ET AL: "Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4956 - 4964, XP002128611, ISSN: 0008-5472
• [A] SCHWARTZ S M: "Cell death and the caspase cascade.", CIRCULATION. 27 JAN 1998, vol. 97, no. 3, 27 January 1998 (1998-01-27), pages 227 - 229, XP002298456, ISSN: 0009-7322
• [A] LOS M ET AL: "REQUIREMENT OF AN ICE/CED-3 PROTEASE FOR FAS/APO-1-MEDIATED APOPTOSIS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 375, no. 6526, 4 May 1995 (1995-05-04), pages 81 - 83, XP000574811, ISSN: 0028-0836
• [AD] GAMEN S ET AL: "Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 360 - 364, XP004261485, ISSN: 0014-5793
• [AD] VILLA P ET AL: "Caspases and caspase inhibitors", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 22, no. 10, 1 October 1997 (1997-10-01), pages 388 - 393, XP004091999, ISSN: 0968-0004
• [A] KAWAHARA ATSUO ET AL: "Fas-induced DNA fragmentation and proteolysis of nuclear proteins", GENES TO CELLS, vol. 3, no. 5, May 1998 (1998-05-01), pages 297 - 306, XP002298457, ISSN: 1356-9597
• See references of WO 0045165A1

Cited by
CN109862891A

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0045165 A1 20000803; AU 2864100 A 20000818; EP 1151295 A1 20011107; EP 1151295 A4 20050330

DOCDB simple family (application)
US 0002329 W 20000201; AU 2864100 A 20000201; EP 00907081 A 20000201